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Abstract
Since it was discovered, the citric acid cycle has been known to be central to cell metabolism and energy homeostasis.
Mainly found in the mitochondrial matrix, some of the intermediates of the Krebs cycle are also present in the blood
stream. Currently, there are several reports that indicate functional roles for Krebs intermediates out of its cycle. Succinate,
for instance, acts as an extracellular ligand by binding to a G-protein coupled receptor, known as GPR91, expressed in
kidney, liver, heart, retinal cells and possibly many other tissues, leading to a wide array of physiological and pathological
effects. Through GPR91, succinate is involved in functions such as regulation of blood pressure, inhibition of lipolysis in
white adipose tissue, development of retinal vascularization, cardiac hypertrophy and activation of stellate
hepatic cells by ischemic hepatocytes. Along the current review, these new effects of succinate through GPR91
will be explored and discussed.
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Background
Back in the 1920’s, succinate (succinic acid in blood pH),
a dicarboxylic acid, was firstly correlated to a carbohy-
drate oxidation sequence proposed by Thorsten Thun-
berg, 1920 [1]. In the following decade, this sequence of
oxidation was better described thanks to Albert von
Szent-Györgyi’s studies on pigeon breast muscle [2].
Consequently, succinate’s catalytic role as a hydrogen
carrier in aerobic respiration was discovered [2]. Then,
in the late 1930’s, Krebs described the core of aerobic
respiration, the Krebs cycle – also referred to as tricarb-
oxylic acid cycle or citric acid cycle [3]. With a few pos-
terior details added, this cycle remains the best
description of aerobic respiration to date [4]. Thereafter,
for many decades succinate had been considered only as
an intermediate of Krebs cycle, which was thought to be
its single synthesis pathway.
Recent studies, however, demonstrated that succinate
could be produced in nonenzymatic manners as well.
This is possible because, under oxidative stress condi-
tions, in which some enzymes of the Krebs cycle are
inhibited, α-ketoglutarate levels are alternatively gener-
ated via transamination. Its accumulation combined with
inactivation of α-ketoglutarate dehydrogenase – from
the Krebs cycle – leads to nonezymatic decarboxylation
of α-ketoglutarate into succinate [5]. It is noteworthy
that in 1970, Krebs noticed that some of the Krebs’
metabolites, including succinate, could accumulate in
the interstitial space in case of ischemia, although the
mechanisms and metabolic implications were not com-
pletely explained at the time [6]. Recently, Chouchani
and colleagues (2014) described a mechanism by which
extracellular concentration of succinate augments in
case of ischemia (Fig. 1). 13C-isotopologue labelling
assessments indicated that succinate was not generated
by the common sources used in normoxia, which
include glucose, glutamate, fatty acids and GABA (γ-
aminobutyric acid) shunt. Moreover, these authors found
that infusions of dimethyl malonate, the precursor of
malonate – a competitive inhibitor of succinate dehydro-
genase – caused decrease in succinate accumulation,
altogether demonstrating that succinate increases during
ischemia is due to succinate dehydrogenase reverse
action, reducing fumarate – generated from malate/as-
partate shuttle and the purine nucleotide cycle, since
both this pathways are favored by ischemic conditions -
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into succinate [7, 8], (Fig. 1). Thus, succinate is an im-
portant intermediate metabolite of the citric acid cycle
that can be generated by different pathways within the
mitochondria. In conditions linked to insufficient blood
supply, such as ischemia, succinate is generated through
a pathway distinct from Kreb’s cycle, and its concentra-
tion at blood vessels might rise.
Hence, once accumulated within the mitochondrial
matrix, succinate can migrate to the cytosol through
dicarboxylate transporters located in the inner mito-
chondrial membrane. SLC25A10 (solute carrier family
25 member 10), a succinate-fumarate/malate transporter,
is considered hitherto the responsible for this transloca-
tion. The second phase of transport, in which succinate
crosses the outer mitochondrial membrane, is thought
to happen by means of porins, namely, proteic channels
through which various nonspecific molecules of less
than 1.5 kDa may pass. Lastly, succinate has a fast efflux
system into the bloodstream. The transporter, a protein
named INDY (for I’m not dead yet, on account of its
apparent relation to longevity), is a sodium-independent
anion exchanger [9] (though previous studies considered
it a sodium-coupled transporter) [10], which is able to
switch dicarboxylates and citrate across the cell membrane.
Why are these alternative ways of succinate synthesis
and its transport mechanism relevant? Mainly, because
of the several functions attributed to succinate other
than participating in the Krebs cycle, some of them –
the ones on which this paper will focus – are associ-
ated with a G protein-coupled receptor, known as
GPR91or SUCNR1, which has succinate as its specific
ligand [11]. Upon binding to such receptor, succinate
has a hormone-like function acting in various organs
and tissues such as blood cells, adipose tissue, liver,
heart, retina, and kidneys – being expressed the most
in these latter [11].
An overview on GPR91 and its expression pattern
GPR91 is a G-protein coupled receptor that acts as a
sensor of extracellular succinate [11; reviewed in 12].
When it comes to the receptor structure, mutation
experiments demonstrated that Arg99, His103, Arg252 and
Arg281 play an important role in receptor function.
These amino acids are all located in helices and agglom-
erate in the central area of the receptor - a rhodopsin-
like structure - in a way that the positive charge attracts
succinate [11]. We now show the result of an in-silico
study of GRP91 and its possible succinate-binding site
(Fig. 2). Although GPR91 is 33 % homologous to GPR99,
a receptor linked to α-ketoglutarate, affinity assays have
shown that succinate binds exclusively to GPR91, while
α-ketoglutarate is a ligand for GPR99 [11]. In fact, the
EC50 values regarding succinate-GPR91 stimulation
range from 20 to 50 μm [11]. To test GPR91 ligand
binding affinity, several substances, including pharmaco-
logical compounds for different GPCRs, and carboxylic
acids close to succinate were tested. Some of them could
also bind to GPR91, but with a much lower affinity com-
pared to succinate [11–13]. Thus, it is now well accepted
that succinate is the endogenous ligand for GPR91.
GPR91 interacts with multiple G-proteins. According to
some studies using pertussis toxin, GPR91 can couple
either with Gi or Gq, triggering different pathways and ini-
tiating distinct cellular effects. In HEK293 and MDCK
(kidney derived cells), for example, succinate induces
intracellular calcium release, inositol triphosphate forma-
tion, extracellular-signal-regulated kinases 1/2 (ERK1/2)
activation and decrease of cyclic adenosine monopho-
sphate (cAMP) concentration, which are signaling path-
ways induced by Gq or Gi coupling, depending only on
succinate concentration [11]. In hematopoietic progenitor
cells, however, signaling mediated exclusively by Gi/o
leads to proliferation due to ERK1/2 activation [14]. In
Fig. 1 Pathway of succinate accumulation during ischemia/reperfusion. Despite minor production via regular Krebs cycle - which is diminished due to
excessive synthesis of NADH -, the reverse activity of succinate dehydrogenase has been shown to be the leading cause of succinate increase during
ischemia. The sources of fumarate, which is then reduced into succinate, are mainly the Purine Nucleotide cycle – shown on the left - and the Malate/
Aspartate Shuttle – similar to the Krebs cycle to run in reverse, which is favored by high levels of NADH
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cardiomyocytes, succinate increases rather than de-
creases cAMP, leading to protein kinase A (PKA) acti-
vation, and suggesting that GPR91 coupling to Gs is
also possible [15]. These distinct intracellular signaling
pathways initiated by GPR91 activation indicate that
succinate actions as a hormone can indeed be very
diverse. Moreover, after triggering the signal transduc-
tion cascade, GPR91 is known to undergo internaliza-
tion. Imaging studies indicated that GPR91 is located
specifically on the plasma membrane, and is internal-
ized and then desensitized as a result of ligand stimula-
tion [11; reviewed in 12].
Although, GPR91 was initially characterized in the
kidney, and shown to be highly expressed in liver, spleen
and intestine [11], GPR91 is now known to be present
throughout the body, including a variety of excitable as
well as non-excitable cells. In the kidney, GPR91 local-
izes to the renal vascular lumen, in particular the affer-
ent arteriole and the glomerular vasculature. Moreover,
GPR91 is expressed in the luminal membrane of mul-
tiple segments of the renal tubules: the cortical thick
ascending limb (CTAL) of Henle’s loop, including the
apical membrane of macula densa (MD), and the cortical
and medullary collecting duct (CD) [16–18], but renin-
producing juxtaglomerular cells (JGA), mesangial cells,
and vascular smooth muscle cells that are key compo-
nents of the JGA were found to be GPR91 negative [17].
In the liver, GPR91 is exclusively expressed in quiescent
hepatic stellate cells (HSCs) [19], while in the heart
ventricular cardiomyocytes express GPR91 in the sarco-
lemma membrane and T-tubules [15]. In the retina,
GPR91 is predominantly expressed in the cell bodies of
the retinal ganglion cell (RGC) layer [20]. White adipo-
cytes, hematopoietic progenitor cells [21] and multiple
types of blood and immune cells were reported to
express GPR91 [14, 22]. GPR91 was also detected in
immature dendritic cells (DCs). Thus, since its
characterization as the receptor for succinate in 2004
[11], GPR91 has been described in many cell types,
and demonstrated to have a vast array of functions in
the human body. Further details regarding the role of
succinate through GPR91 in some of the aforemen-
tioned systems will be discussed below.
GPR91 signaling in the liver
The liver is targeted by a high number of growth factors
and hormones that bind directly to hepatocytes or to
other cell types such as HSCs. Many of these molecules
(PDGF and TGF-β, for example) activate stellate cells
during liver damage. Also, non-traditional signals such as
matrix stiffness, metabolites and oxidative stress [23] are
able to activate HSCs. A study published in 2007 by
Correa and colleagues suggesting that succinate may
behave as a metabolic sensor in the liver, has extended our
comprehension of how liver injury can stimulate succinate
production and consequent HSC activation [19]. Accord-
ing to Correa et al., 2007, in vitro ischemia-reperfusion in
rodent livers, allowed detection of succinate in extracellu-
lar fluids, and this phenomenon played an important role
in the activation of HSCs (Fig. 3). The same group showed
that, in the liver, GPR91 is expressed primarily in the
quiescent stellate cell and this expression is lost when stel-
late cells are activated. On the other hand, Li et al., 2015
showed that in the presence of succinate, HSCs present an
Fig. 2 Schematic model of the GPR91 active site. Surface representation of succinate binding at the active site with electrostatic potential (red,
blue for negative and positive potential, respectively) computed with the GPR91 tool in Website Protein Data Bank (PDB). a through c represent
consecutive higher magnifications of the succinate binding site on GPR91
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increased GPR91 expression followed by a 2-fold
increase in the differentiation rate, thus leading o their
activation [24].
In addition, Li and colleagues 2015, expanded the pre-
vious finding, by demonstrating the specific molecular
effects of succinate in the activation of HSCs. On a study
using in vitro and in vivo models, it was shown that
HSCs cultured and treated directly with succinate or
with inhibitors of succinate dehydrogenase (malonate,
palmitate/choline and methionine-choline deficient media),
caused not only an increase in expression of GPR91, but
also of alpha-smooth muscle actin (α-sma), TGF-B
and collagen type I, markers of a fibrogenic response
[24] (Fig. 3). On the other hand, transfection of these
cells with siRNA for GPR91 abrogated α-sma produc-
tion induced by succinate, indicating the specificity of
the pro-fibrogenic responses to GPR91 signaling. In
the in vivo studies, HSCs isolated from hepatosteatotic
mice, fed with a methionine and choline deficient diet,
released a higher level of succinate and expressed
more GPR91 and α-sma as well. Taking together, these
findings indicate a succinate-GPR91 coupling depend-
ence in HSCs activation and fibrogenesis. Therefore,
GPR91 might play a relevant role in liver homeostasis,
being a possible therapeutic target for modulation of
hepatic functions. Blocking GPR91 during liver trans-
plantation could, for instance, avoid undesirable fibro-
genic reactions.
GPR91 signaling in retina
Besides liver injury, succinate effects through GPR91
activation have been demonstrated in a very delicate and
well-specialized structure such as retina, which owns a
vast vascular plexus responsible for its metabolic require-
ments [25]. In certain conditions, a misbalance between
tissue demand for oxygen and nutrients and vascular sup-
ply results in hypoxic retina, leading to a detrimental pre-
retinal and intravitreal neovascularization. Since vascular
supply is coupled to tissue metabolic rate, and succinate
accumulates under conditions of insufficient oxygen
supply [26, 27], the role of succinate in retinal neovascu-
larization induced by hypoxia was investigated. It was
found that in ischemic retinas of rats subjected to oxygen-
induced retinopathy, succinate levels rise without a joint
increased expression of GPR91, which maintained its
levels in retinal ganglion neurons (the main retinal
structure where GPR91 is localized) [20]. In addition,
succinate induced a prominent development in retinal
vascularization and vascular density, an effect signifi-
cantly suppressed by siRNA to GPR91. In this report,
Sapieha and colleagues, 2008, showed that the role of
succinate in this system is to induce an autocrine acti-
vation of retinal ganglion neurons by its binding to
GPR91. Therefore, in response to augmented succinate
levels, these cells regulate the production of an array of
angiogenic factors including the vascular endothelial
growth factor (VEGF) through a specific activation of
Fig. 3 Succinate role in the liver through GPR91. During an ischemic condition, succinate is released by anoxic hepatocytes and binds to stellate cells
leading to their activation. Once activated, stellate cells increase expression of several fibrogenic markers, such as alpha-smooth muscle actin (α-sma),
TGF-B and collagen type I
de Castro Fonseca et al. Cell Communication and Signaling  (2016) 14:3 Page 4 of 9
GPR91. Of note, there is no participation of a hypoxia-
inducible factor-1a (HIF-1a)-dependent pathway (Fig. 4).
Accordingly, succinate showed no effect on rats that
are deficient in retinal ganglion neurons, confirming
the importance of these cells in orchestrating GPR91-
succinate-dependent neovascularization. Conversely to
succinate effects, Semaphorin 3A (a class of secreted
and membrane protein that acts as an axonal growth
cone guidance molecule) has been suggested as an
opposite force to neovascularization [28]. Joyal et al.,
2011, suggested that this molecule promotes vascular
decay and later forms a chemical barrier that repels
neo-vessels toward the vitreous [28].
Adding on the succinate effects on retinal neovascular-
ization described above, Hu et al., 2013 have shown that
GPR91 also regulates VEGF production in the retinal
cell line RGC-5 through its direct incubation with
succinate or a high-glucose medium [29]. In addition,
ERK1/2 and JNK signaling pathways may be involved in
the effects of GPR91-mediated high glucose-induced
VEGF release in RGC-5 cells. A very recent work from
the same group reinforced these findings. Using RGC-5
cells, Hu et al., 2015, demonstrated that GPR91 mediates
VEGF secretion and endothelial cell proliferation, pos-
sibly by activating the ERK1/2 and JNK signaling path-
ways and then upregulating COX-2 (Cyclooxygenase 2)
and PGE2 (prostaglandin E2) expression [30]. Since
COX-2 gene encodes a cytosolic protein that is upregu-
lated throughout inflammation and may contribute to
local ischemia and hypoxia, a higher COX-2 expression
suggests that inflammation has an important part in the
incidence and evolution of diabetic retinopathy [30].
In summary, strong evidence has put succinate/GPR91
as an important signaling pathway to activate the devel-
opment of new blood vessels in retina during a hypoxic
condition and modulation of VEGF release through this
process might be a possible target for therapy.
GPR91 signaling and metabolism
The effects of GPR91 signaling pathways on metabolism
were first demonstrated by Sadagopan, 2007. By using
rodent models of diabetes, obesity and hypertension, it
was demonstrated that circulating succinate levels in
these animals are elevated compared to non-diseased
controls [31]. However, the mechanisms that lead to this
increase in succinate concentration remain unclear. Con-
trary to what was observed in rodents, neither hyperten-
sion nor diabetes was associated with a rise in circulating
succinate in human blood samples [31]. While these
observed differences were not elucidated yet, another study
using blood samples from patients that underwent liver
transplantation showed increased levels of succinate as
early as 2 h post-transplant, which was also observed 6 h
after transplant [15].
More recently, McCreath and colleagues, 2015, showed
that GPR91 is vastly expressed in the white adipose tissue
of mice and regulates adipose mass and glucose homeo-
stasis [32]. By generating a GPR91mutant mouse, it was
shown that loss of succinate receptor leads to dichotom-
ous effects on metabolism and total body weight, with no
Fig. 4 GPR91 activation induces retinal neovascularization in ischemic proliferative retinopathy. Under normal conditions, retina presents a basal
vascularization. (1) During hypoxia, succinate accumulates and (2) binds to GPR91 on RGCs, leading to (3) proangiogenic factor production that
stimulate the development of new vessels (4) in order to restore the vascular supply to the hypoxic retina
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difference of weight among organs, but with a marked
difference on the cumulative fat content [32]. On a regular
diet, Sucnr1-/- mice present a smaller white adipose tissue
compartment, smaller adipocytes, increased energy ex-
penditure and an improved glucose buffering. Although it
could be thought that decreased expression of GPR91
would lead to a reduced expression of genes related to adi-
pocyte differentiation, deletion of GPR91 did not alter
adipogenesis but rather resulted in diminished lipid accu-
mulation and smaller adipocyte size. These results were
further evaluated by the VO2 test, to investigate the meta-
bolic changes caused by GPR91 deletion. As expected, the
rate of VO2 consumption was reduced in Sucnr1-/- mice
compared to WT counterparts. In contrast, feeding
Sucnr1-/- mice with a high fat diet leads to increased fat
deposition, hyperglycemia, reduced insulin secretion and
an augmented hepatocyte damage compared to wild-type
(WT) littermates. Thereby, these findings put GPR91 as a
sensor for dietary energy, being a possible target for thera-
peutics on obesity, hypertension and diabetes.
GPR91 signaling in the heart
Succinate is an important molecule for the maintenance
or disturbance of cardiovascular status, specially blood
pressure and cardiac muscle thickness. In 2010, Aguiar
and collaborators showed that GPR91 is expressed in
ventricular cardiomyocytes, in the sarcolemmal mem-
brane, and in T-Tubules [33]. Because the GPR91 recep-
tor is expressed in cardiomyocytes, and cardiac function
is an important determinant of blood pressure and other
aspects of cardiovascular homeostasis, there was an urge
to investigate the role of succinate through cardiac GPR91.
Aguiar et al. in 2010 showed that succinate could directly
activate GPR91 in cardiomyocytes, affecting the pattern of
intracellular Ca2+ release and Ca2+ re-uptake. It was dem-
onstrated that proteins such as phospholamban and ryano-
dine receptor, both well known to be involved in the
dynamic of cardiomyocyte Ca2+ release, are activated by
succinate/GPR91 interaction. These effects were triggered
by adenylyl cyclase and consequently PKA activation,
resulting in cardiomyocyte apoptosis [33], an event that
was prevented by PKA inhibitor. Together, these results
confirmed that succinate could indeed, at high concen-
tration, lead to cardiomyocyte cell death. Moreover,
these data suggested that increased levels in serum suc-
cinate, which could be triggered for instance in ische-
mic conditions, might represent an important cause of
cell death in the heart.
Furthermore, in 2014 it was demonstrated that long-
term exposure to succinate could lead to cardiomyocyte
hypertrophy [15]. Since activation of GPR91 in kidney can
increase blood pressure through the renin-angiotensin
system (RAS) [11], the question remained whether cardiac
hypertrophy, induced by high levels of succinate in the
blood stream, was a consequence of succinate-induced
changes in mean arterial blood pressure (MAP) through
RAS activation, rather than a direct effect of succinate
through GPR91 in the heart. It was found that MAP was
unaffected after two days of succinate treatment, but
slightly increased at day 4, and reverted to normal values
on the final day of the experiment indicating that the
observed hypertrophy induced by succinate was therefore
not entirely due to an increase in MAP, but could involve
other mechanisms as well [15]. Moreover, echocardiog-
raphy experiments in rodents, in the presence or absence
of losartan, which is an antagonist for the angiotensin II
receptor AT-1, demonstrated that losartan abolished
succinate-induced increase in blood pressure but did not
alter the most relevant echocardiographic parameter for
measuring hypertrophy (left ventricular posterior wall
thickness - LVPW). These findings were consistent with
previous results that showed that succinate could induce
RAS activation, but also indicated that succinate-induced
hypertrophy was not solely caused by variations in MAP.
To connect cardiac hypertrophy to succinate-GPR91
activation, experiments with GPR91-KO mice were
performed and showed an increase in left ventricular
posterior wall only in wild type mice, but not in
GPR91-KO mice. These findings demonstrated that
GPR91 is essential for succinate-induced cardiomyocyte
hypertrophy. Taken together, these results show that
upholding levels of serum succinate can cause cardiac
hypertrophy through direct activation of GPR91. How-
ever, the fact that losartan reversed some of the other
observed hypertrophic effects (besides LVPW) also sug-
gests that succinate-induced remodeling of cardiac
muscle involves direct effects of GPR91 in cardiac cells,
but also succinate effects in other organs.
The intracellular signaling events by which GPR91
activation causes cardiac hypertrophy were thus estab-
lished, using primary culture of neonatal cardiomyocytes
[15]. It was shown that upon binding to GPR91, succin-
ate causes CaMKIIδ and ERK1/2 activation, culminating
in the transcription of genes related to cardiac hypertrophy
[15], (Fig. 5). Succinate/GPR91 activates phospholipase C,
which generates inositol 3,4,5-triphosphate (IP3) and
triggers intracellular Ca2+ release from the endoplasmic
reticulum (ER). Cytoplasmic Ca2+ then activates CaMKIIδ,
which phosphorylates histone deacetylase 5 (HDAC5),
translocating it out of the nucleus, facilitating the transcrip-
tion of hypertrophic genes (Fig. 5). Additionally, GPR91
activates MAPK, which phosphorylates ERK1/2. Phosphor-
ylated ERK1/2 (pERK 1/2) translocates to the nucleus,
where it also induces cardiac hypertrophy through the
aforementioned hypertrophic cellular signaling cascades in
cardiomyocytes. Other mechanisms, still not explored,
might likewise be involved in succinate/GPR91-induced
cardiomyocite hypertrophy.
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In addition to these findings in rodent models, it was
also demonstrated that humans that underwent a recent
ischemic event during organ transplantation, have in-
creased serum succinate levels, and, accordingly, such
patients have high levels of blood hypertrophic markers
[15]. The clinical applications of these data still need to
be explored, but this preliminary finding suggests that
succinate could be used as a predictive marker for
hypertrophy, and could also be a possible treatment tar-
get to eliminate post-ischemic cardiac hypertrophy, often
observed after organ transplant.
In this aspect, pioneer systematic structure-activity
relationship studies have already identified compounds
able to abolish GPR91 function both in human and rats
[13]. A compound known as “4c” showed the best
antagonic effect in vitro (IC50 = 7nM), and also regu-
lated in almost 80 % mean arterial blood pressure vari-
ation caused by succinate. Different compounds with
similar structure, referred to as “5g” and “7e”, remained
active after oral intake, a positive result for future
pharmacological use. A remarkable fact about theses
antagonists is that none of their structures resemble
succinate. Given that, the binding mechanism is hith-
erto not fully understood [12].
GPR91 signaling in the kidneys and its effects on
blood pressure
Besides acting in the heart to contribute to ventricular
hypertrophy, succinate can be a potent modulator of
renin release. Previous findings by He et al. in 2004,
encountered elevated blood pressure in mice treated
with succinate. However, the mechanism that led to such
increase had not yet been found [11]. Recent work by
Vargas et al. in 2009 has finally elucidated the way in
which this increase in MAP happens in succinate-
treated mice. The experiments showed that accumula-
tion of tubular succinate in the kidneys can activate
Macula Densa (MD) cells and cells in the juxtaglomeru-
lar apparatus (JGA) to release renin, which is a known
pathway for increasing blood pressure via vasoconstric-
tion of peripheral arteries [17]. In this pathway, succin-
ate binds to its receptor GPR91 in the apical region of
the MD cells, activates p38 and pERK1/2, which in turn
increases COX-2 activity and leads to PGE2 secretion.
This release stimulates the cells in the JGA to produce
and release renin, acting through the EP2/4 prostaglan-
din receptors and cAMP, thus activating the known
renin-angiotensin system (RAS). This modulation of
blood pressure also happens in endothelial cells in the
Fig. 5 Succinate causes cardiomyocyte hypertrophy via GPR91 activation. Succinate accumulation in the blood stream reaches the cardiac muscle
cells to activate GPR91, consequently triggering at least two separate intracellular signaling pathways. In one pathway, GPR91 stimulates MEK1/2
that phosphorylates ERK1/2. Phosphorylated ERK1/2 is translocated to the nucleus, where it activates transcription of hypertrophic genes. In an
alternative pathway, GPR91 activates PLC, which produces inositol-3-phosphate and diacylglycerol. IP3 binds to its receptor, releasing Ca2+ from
the sarcoplasmic reticulum to the cytosol. Ca2+ activates CaMKIIδ that moves to the nucleus and phosphorylates HDAC5, which is released from
transcription factor MEF2 allowing the transcription of hypertrophic genes
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kidney, especially in the afferent arteriole and the glom-
erular vasculature, where succinate acts through the
highly expressed GPR91, increasing Ca2+ transient and
releasing PGE2, PGI2 (prostacyclin 2) and NO (nitric
oxide), which causes renin release in the JGA [19]. A re-
cent microperfusion study has shown that perfusion of
the glomeruli with a succinate buffer induces renin re-
lease from the JGA and vasodilation of the glomerular
afferent arterioles, which abides by the affirmation that
succinate has an essential role in glomerular hyperfiltra-
tion and RAS activation.
These data suggest that succinate not only has a
very important role in blood pressure regulation in
ischemic events, but could also be a possible target
for novel therapies to control hypertension. For
example, post-ischemic transplanted patients could
receive GPR91 antagonists to prevent a possible
increase in MAP during recovery. That strategy,
combined with known treatments for prevention of
post operational hypertension, could reduce the car-
diovascular risk for other chronical conditions such
as arteriosclerosis and aneurisms, both implicated in
long-term increases in blood pressure.
Perpectives in the succinate/GPR91 field
Some evidence has pointed succinate as an ‘alarming’ signal
able to trigger GPR91 to sense immunological danger, caus-
ing increased allograft rejection during organ transplant-
ation [21]. As described above, blood level of succinate is
increased in the serum of patients after liver transplant
[15]. Also, a deficiency on mitochondrial succinate cyto-
chrome C reductase, a genetic condition that leads to an
increase in succinate levels on serum, is reported as a need
for special attention in transplant procedures, since the
donor could possibly transfer this inherited metabolic
disorder to the recipient [34]. This is a fundamental
concern when the donor has parental consanguinity, an
increasing factor for autosomal recessive illnesses such as
the above-mentioned one. In addition, a multiorgan failure
has been reported in a liver-intestine transplant from a
pediatric donor with a succinate- cytochrome C-
reductase deficiency, a condition that would lead to
an increase in blood succinate level. It has also been
demonstrated that a patient with succinate dehydro-
genase deficiency, another condition that also leads
to extracellular accumulation of succinate, exhibited
congestive heart failure [35]. Then, GPR91 antagon-
ism in preservation solution for transplantation could
represent, for instance, a real benefit to help prevent-
ing rejection or other complications.
Thereby, succinate may be a clinical marker for
ischemia, and its increase in blood level due to
organ transplant should be avoided.
Conclusions
Since the discovery and characterization of GPR91 - a
G-protein couple receptor for succinate - a decade ago,
succinate signaling through GPR91 increased our under-
standing of body functions. It is worth to mention that
succinate is now more than sole particpant as a meta-
bolic intermediate. It is known that circulating succinate,
through GPR91 activation, is extensively involved in sev-
eral physio-pathological functions, as shown along this
review. Thus, succinate may be considered a signaling
molecule with a hormone-like function. Since blood
succinate level increase mainly due to ischemia/reperfu-
sion, an emerging application during organ transplant-
ation becomes evident. Therefore, understanding better
the participation of Krebs cycle intermediates, as signal-
ing molecules, and their relative contribution to each
physiological process in which they might be involved,
may lead to a clearer understanding of cell function, and
to more accurate clinical interventions when necessary.
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apparatus; JNK: c-Jun N-terminal kinases; LVPW: Left ventricular posterior wall;
MAP: Mean arterial blood pressure; MD: Macula densa; PDGF: Platelet-derived
growth factor; PERK 1/2: Phosphorylated extracellular signal regulated kinase 1/2;
PGE2: Prostaglandin E2; PGI2: Prostacyclin 2; PKA: Protein kinase A; CTAL: Cortical
thick ascending limb; RAS: Renin-angiotensin system; RGC: Root ganglion cell;
siRNA: Small interference ribonucleic acid; SUCNR: Succinate receptor;
TGFβ: Transforming growth factor beta; VEGF: Vascular endothelial growth factor;
VO2: Oxygen consumption; WT: Wild-type.
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